KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Interest Expenses (2023 - 2025)

Biocryst Pharmaceuticals' Interest Expenses history spans 8 years, with the latest figure at $14.1 million for Q4 2025.

  • For Q4 2025, Interest Expenses fell 42.19% year-over-year to $14.1 million; the TTM value through Dec 2025 reached $78.9 million, down 19.94%, while the annual FY2025 figure was $78.9 million, 19.94% down from the prior year.
  • Interest Expenses reached $14.1 million in Q4 2025 per BCRX's latest filing, down from $19.7 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $104.4 million in Q4 2023 to a low of $14.1 million in Q4 2025.
  • Average Interest Expenses over 3 years is $31.3 million, with a median of $24.4 million recorded in 2024.
  • Peak YoY movement for Interest Expenses: plummeted 76.58% in 2024, then fell 4.13% in 2025.
  • A 3-year view of Interest Expenses shows it stood at $104.4 million in 2023, then tumbled by 76.58% to $24.4 million in 2024, then plummeted by 42.19% to $14.1 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Interest Expenses are $14.1 million (Q4 2025), $19.7 million (Q3 2025), and $21.6 million (Q2 2025).